Roche's Genen­tech touts la­bel ex­pan­sion for block­buster lung can­cer drug Ale­cen­sa

Roche’s Genen­tech said that Ale­cen­sa scored a la­bel ex­pan­sion from the FDA, with the drug now ap­proved as an ad­ju­vant treat­ment fol­low­ing tu­mor re­sec­tion in pa­tients with ALK-pos­i­tive non-small cell lung can­cer.

The ap­proval is based on da­ta from the Phase 3 ALI­NA study that showed Ale­cen­sa re­duced the risk of dis­ease re­cur­rence or death by 76% com­pared to those in the con­trol arm who re­ceived chemother­a­py fol­low­ing surgery.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER